How to improve therapy for adult acute myeloid leukemia: studies of the AML Cooperative Group in the Federal Republic of Germany.
Büchner
T
T
Department of Internal Medicine, University of Münster, Federal Republic of Germany.
Hiddemann
W
W
Maschmeyer
G
G
Ludwig
W
W
Löffler
H
H
Nowrousian
M
M
Aul
C
C
Heinecke
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D015996:Survival Rate; D013866:Thioguanine / Q000627:therapeutic use
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013866:Thioguanine; D003630:Daunorubicin